HGH Injections For Sale

UK trade negotiators will not give in to Canadian demands that beef produced with artificial growth hormones be allowed onto the British market.

Orkney and Shetland MP, Alistair Carmichael, this week claimed to have secured a commitment from the UK International Trade Secretary that a continued ban on hormone-treated beef would be a 'red line' in UK-Canada trade negotiations.

The Secretary of State, Anne-Marie Trevelyan MP, made the commitment in response to a letter from Mr Carmichael which highlighted claims from Canadian negotiators that overturning the ban would be their goal during trade talks.

Read more:

In her letter, the Secretary of State said: Maintaining our high standards and protecting the UKs right to regulate is a red line in all our trade negotiations, as most recently outlined in the UKs Strategic Approach to the UK-Canada negotiations. All imports into the UK must meet our stringent food safety standards, including the existing ban on hormone-treated beef.

Mr Carmichael said: I am glad that the Secretary of State has responded in no uncertain terms that hormone-treated beef will not be coming into the UK regardless of Canadian trade talks. This is not just a red line for the government but a red line for farmers and crofters and indeed consumers who do not want to see our food standards hollowed out.

The minister really could not have been much clearer and so we have a right to hold her to her word. There can be no backtracking or reinterpretation of this commitment, no matter how much of a priority it may be for our Canadian partners. The government has not lived up to its past commitments to farmers and food producers during negotiations with Australia and New Zealand they must raise their game now.

Originally posted here:

Carmichael claims victory on hormone-treated beef - The Scottish Farmer

While short-term melatonin use is considered safe for most people, there is limited research to show that it is effective for promoting sleep long term. And beyond being ineffective, taking melatonin every night can be harmful.

"It's important to remember that melatonin is a hormone and using any hormone regularly can down-regulate your own production of that hormone," notes Bonney.

"I have not seen good data to show that high doses of melatonin will not impact your endogenous, natural production of melatonin," echoes Ashley Jordan Ferira, Ph.D., RDN, mbg's vice president of scientific affairs.

Furthermore, initial research has found that melatonin supplementation may negatively affect the function of other hormones likeestrogenandmale growth hormone.

Considering its potential to throw off hormone health, it makes sense that melatonin is only available as a prescription in most countries. "Melatonin is a hormone and should be used intentionally, ideally under the guidance of a licensed health professional," says Bhopal.

So consider this sleep myth squashed: You should not take melatonin every night.

Follow this link:

If You're Taking Melatonin Every Night, You're Going To Want To Read This - mindbodygreen.com

Silver-Russell syndrome (SRS) is a rare genetic disorder with an estimated prevalence of 1/100,000 [1,2]. It combines severe intrauterine growth retardation, postnatal weight-bearing delay, craniofacial dysmorphia, and limb asymmetry grouped in the Netchine-Harbison score [1]. Its etiology is an anomaly ofparental imprinting [3].Its management is based on symptomatic treatment, growth hormone use, and/or bone lengthening surgery in the hope of relieving the psychological suffering of patients [3]. We report the observation of a patient, in whom this syndrome is associated with thyroid ectopy, not reported before in the literature.

We report the case of a 16-year-old patient from a non-consanguineous marriage. He was admitted to the hospital for investigation of a stature-ponderal delay. The interrogation revealed intrauterine growth retardation with low birth weight and profound mental retardation (IQ < 70) evolving since birth. The patient also has a delay in psychomotor development, walking, and closure of the anterior fontanel without eating difficulties or hypoglycemia. There is no similar case in the family, and there is no family history of thyroid ectopy or hypothyroidism.The clinical examination revealed a stature-ponderal delay: weight, -2.8DS; height, -4DS; and BMI, 14.8 kg/m2 (underweight according to the International Obesity Taskforce (IOTF) curve) in a patient at the beginning of puberty.The patient presented a dysmorphic syndrome made of a triangular face: a prominent forehead, cranial perimeter at +1.8DS, and ogival palate without dental anomalies. He has body asymmetry, as can be seen in Figure 1 (trunk asymmetry) and Figure 2 (limb asymmetry).

The left arm measures 61 cm, the right arm measures 62 cm, and the right lower limb is 83 cm longer than the left by 3 cm, with a scoliotic attitude with flat feet. Based on this clinical assessment, the Netchine-Harbison score was 6/6 [1]. The biological workup showed profound hypothyroidism with TSH of 100 mUi/L, LT4 of 0.45 ng/mL (normal range: 0.7-1.48 ng/mL), and anti-thyroidperoxidase (TPO) antibodies of 0.30 IU/mL< 5.61. An old thyroid checkup was normal according to the family, but we had no documents. Ultrasound images passing the upper limit of the hyoid bone showed a well-limited, roughly oval, homogeneous tissue structure measuring 21 9 mm, reminiscent of thyroid parenchyma, and the thyroid compartment was empty on ultrasound exploration as can be seen in Figure 3.

Radiological exploration showedcoxal bone irregularity bilaterally with no other renal, cardiac, or genital malformations. The bone age was estimated at 14 years with a two-year lag. The patient was put on L-thyroxine thyroid axis replacement and underwent TSHmonitoring along with a genetic study.

Silver-Russell syndrome (SRS) was first described in 1953 [2]. It combines severe intrauterine growth retardation, postnatal weight-bearing delay, a particular facial dysmorphia, and limb asymmetry [3]. Our patient presents a heightandweight delay with dysmorphic syndrome and body asymmetry, which was also reported in the literature [4,5]. In the study of Price et al. [6], 34% were asymmetrical, with a limb length discrepancy greater than 0.5 cm. Limb circumference was also affected in all of these cases. All asymmetrical subjects had a classical facial appearance. The lower limb was involved in all cases. Ten patients also had upper limb asymmetry, and in these, truncal and facial asymmetry was more often noticeable. The maximum leg length difference was 2.5 cm, whereas in our patient, the difference in the lower limbs was 3 cm, which was not previously reported in the literature.In another study [7], the authors showed that all patients with body asymmetry had scoliosis, which was also noted in our patient. Other manifestations were reported in the series [8,9], such as syndactyly of the second and third toes, clinodactyly, anorexia, and migraine, which were not found in our patient.

The clinical diagnosis of SRS is suspected when four out of six criteria of the Netchine-Harbison score [1] are present and molecular confirmation testing is warranted. It can stratify patients with SRS into subgroups, which can lead to more tailored management. However, molecular investigations come back negative in a notable proportion of patients with characteristic clinical features of SRS [7]. In our case study, we confirm the diagnosis of Silver-Russell syndrome based on the clinical description, and a genetic study is underway.

The mutations responsible for SRS are molecular abnormalities of the genes coding for fetal growth factors [10,11], by loss of methylation of the 11p15 chromosomal region 5 in 30%-60%, maternal uniparental disomy of chromosome 7 in 5%-10%, and chromosomal rearrangements involving imprinting center 1 (IC1) [11]. Other genetic abnormalities have been described, such as chromosome 15 deletion or chromosome 19 translocation. Most cases of Silver-Russell syndrome are sporadic [12,13]. The heterogeneity of the molecular abnormalities is at the origin of several phenotypes [14]. SRS is associated with several congenital malformations: genital, cardiac, gastric, and renal anomalies. However, thyroid malformation has never been reported [15]. Sublingual thyroid ectopy, which is present in our patient, is a rare condition related to a failure of migration of the thyroid gland during embryonic development [16]. The lingual thyroid is the most frequent form [16]. Besides the growth issues, neurodevelopment is of great concern to parents. Evidence shows that children with this condition are at increased risk for developmental delay (both motor and cognitive) and learning disabilities, which was indeed noted in our patient.

The treatment of SRS is symptomatic and multidisciplinary. The administration of growth hormone and surgical treatment by progressive bone lengthening of the femur or tibia by the internal system for functional and aesthetic purposes, indicated only in cases of inequalities of the lower limbs at the end of growth and in adulthood, as comorbidities must also be treated [16]. For thyroid dysgenesis, the treatment is substitutive in the long term. The prognosis is related to malignant degeneration, hence the interest in long-term clinical and biological monitoring [16]. Genetic counseling depends on the underlying molecular mechanism. The risk of recurrence is very low in the case of parental unidisomy of chromosomes [7]. This risk is higher in the case of a mutation of the imprinting center that is transmitted in a Mendelian fashion.

Silver-Russell syndrome is a genetic disease linked to a parental imprinting anomaly. Its diagnosis is essentially clinical. Associated malformations are often described in SRS, hence the interest in a morphological assessment to optimize their management. Genetic counseling depends on the underlying molecular mechanism.Diagnostic difficulties in adulthood should make physicians and healthcare personnel aware of the need to take measurements, especially for newborns, in order to intervene early and improve medical, cognitive, and psychosocial management in childhood.

Original post:

An Unusual Association: Silver-Russell Syndrome and Ectopic Thyroid - Cureus

Prostate Cancer Nuclear Medicine Diagnostics Market Report makes available major statistics on the market status of global and regional manufacturers and is a supportive source for companies and individuals interested in the Prostate Cancer Nuclear Medicine Diagnostics industry. Prostate Cancer Nuclear Medicine Diagnostics Market report has been structured after a thorough study of various key market segments like market size, share, growth, demand, latest trends, market threats and key drivers which drives the market. The careful efforts accompanied with integrated approaches gives an output of such excellent market research report that drives the decision making process of the business. This market report endows with a profound overview of product specification, technology, product type and production analysis by considering most important factors such as revenue, cost, and gross margin.

GlobalProstate Cancer Nuclear Medicine Diagnostics MarketAnalysis and Size

Prostate cancer nuclear medicine diagnostics market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 821.6 million by 2027 and growing rate a CAGR of 7.50% in the above-mentioned forecast period. Market is growing due to the increasing incidence of prostate cancer and reimbursements policies.

Get a Free Sample PDF of This Report (Full TOC, List of Tables & Figures, and Chart) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-prostate-cancer-nuclear-medicine-diagnostics-market

The Segments and Sub-Section of Prostate Cancer Nuclear Medicine Diagnostics Market are shown below:

By Type (Disposable and Reusable), Dosage (Fixed and Variable)

By End-Users (Home Care and Hospitals & Clinics)

By Therapy (Diabetes, Anaphylaxis, Growth Hormone Therapy, Fertility, Arthritis, Osteoporosis, Others)

List of Companies Profiled in the Prostate Cancer Nuclear Medicine Diagnostics Market Report are:

Blue Earth Diagnostics, Lantheus Medical Imagining, Inc, Theragnostics Ltd, Curium Pharma, Jubilant Pharma Limited, NCM-USA LLC, Telix Pharmaceuticals Ltd., Cancer Genetics, Inc, Sun Nuclear Corporation, American Pride, PETNET Solutions Inc., Cardinal Health, ImaginAb .

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart) @ https://www.databridgemarketresearch.com/toc/?dbmr=global-prostate-cancer-nuclear-medicine-diagnostics-market

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at Data Bridge predicts that United States Vendors will contribute to the maximum growth of Global Prostate Cancer Nuclear Medicine Diagnostics market throughout the predicted period.

Key Target Audience

Prostate Cancer Nuclear Medicine Diagnostics Solution Providers, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Frequently Asked Questions (FAQ):

Which factors would majorly drive the Prostate Cancer Nuclear Medicine Diagnostics Market?Rising Disposable Income is seen as one of major growth factors of Prostate Cancer Nuclear Medicine Diagnostics Market in years to come.

Can we have customized study for Prostate Cancer Nuclear Medicine Diagnostics Market?The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Which region will lead the Global Prostate Cancer Nuclear Medicine Diagnostics Market?will lead the Prostate Cancer Nuclear Medicine Diagnostics Market.

Prostate Cancer Nuclear Medicine Diagnostics Market Scope and Market Size

Prostate Cancer Nuclear Medicine Diagnostics market is segmented on the basis of type, dosage, end users, and therapy. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on type, the Prostate Cancer Nuclear Medicine Diagnostics market is segmented into disposable and reusable.

Based on dosage, the Prostate Cancer Nuclear Medicine Diagnostics market is segmented into fixed and variable.

Based on end users, the Prostate Cancer Nuclear Medicine Diagnostics market is segmented into home care and hospitals & clinics.

Based on therapy, the Prostate Cancer Nuclear Medicine Diagnostics market is segmented into diabetes, anaphylaxis, growth hormone therapy, fertility, arthritis, osteoporosis and others.

Strategic Points Covered in Table of Content of Global Prostate Cancer Nuclear Medicine Diagnostics Market Insights by Application, Product Type, Competitive Landscape & Regional Forecast 2029 Market:Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Global Prostate Cancer Nuclear Medicine Diagnostics Market Insights by Application, Product Type, Competitive Landscape & Regional Forecast 2029 market. (Introduction, Scope of the Report)Chapter 2: Exclusive Summary the basi

.Continued

View Detailed Report @ https://www.databridgemarketresearch.com/reports/global-prostate-cancer-nuclear-medicine-diagnostics-market

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Top Related Reports:

Pediatric Dental Crown Market-Share, Size, Regional Trend, Future Growth, Leading Players Updates, Industry Demand by Forecast to 2027

Trauma Devices Market Size, Share, Global Trend, Technological Advancements And Geographical Forecast Till 2029

Travel Vaccine Market Size 2022-Industry Technological Advancements Driving The Industry Share, Trends, Demand, Growth, Segment and Top Players

Laxative Market Size 2022-Industry Opportunities And Challenges, Global And Regional Analysis By Industry Key Players, Key Regions, Sales, Supply 2029

Medical Coding Market Size-Industry Analysis by Key Players, Geography and Opportunities And Challenges, Major Segments Forecast 2029

Oral Mucositis Drugs Market Size 2022-Industry Industry Trends, Growing Demand , Cost Structure, Developments And Forecast 2028

Respiratory Disposables Market Size 2022-Industry Key Areas With Manufacture, Size, Evenue By Countries And Progress Rate 2029

Central Precocious Puberty (CPP) Treatment Market Size 2022-Industry Analysis by Key Players, Geography and Opportunities And Challenges, Major Segments Forecast 2029

Low Vision Aids Market Size-Industry Key Areas With Manufacture, Size, Evenue By Countries And Progress Rate 2027

Spatial Transcriptomics Market 2022- Global Leading Players, Industry Updates, Future Growth, Business Prospects, Forthcoming Developments and Future Investments by Forecast to 2029

Wearable Fitness Trackers Market-Share, Size, Regional Trend, Future Growth, Leading Players Updates, Industry Demand by Forecast to 2027

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Continued here:

Prostate Cancer Nuclear Medicine Diagnostics Market Share Growing Rapidly with Recent Trends, Development, Revenue, Demand and Forecast to 2027 -...

Ipsen S.A. (OTCMKTS:IPSEY Get Rating) was the recipient of a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 600 shares, a decline of 78.6% from the April 15th total of 2,800 shares. Based on an average daily volume of 6,400 shares, the short-interest ratio is currently 0.1 days.

Several equities analysts have commented on the stock. Credit Suisse Group upped their price objective on shares of Ipsen from 87.00 ($91.58) to 105.00 ($110.53) and gave the company a neutral rating in a report on Friday, March 25th. Societe Generale upped their price objective on shares of Ipsen from 112.00 ($117.89) to 120.00 ($126.32) and gave the company a buy rating in a report on Friday, April 29th. Barclays upped their price objective on shares of Ipsen from 88.00 ($92.63) to 95.00 ($100.00) and gave the company an underweight rating in a report on Thursday, April 14th. Bryan, Garnier & Co downgraded shares of Ipsen from a buy rating to a neutral rating in a research note on Wednesday, April 27th. Finally, AlphaValue upgraded shares of Ipsen to a reduce rating in a research note on Thursday, February 17th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the companys stock. According to MarketBeat.com, Ipsen presently has an average rating of Hold and an average price target of $87.25.

IPSEY opened at $23.61 on Friday. Ipsen has a twelve month low of $21.71 and a twelve month high of $32.51. The company has a 50-day simple moving average of $28.81 and a 200 day simple moving average of $26.56.

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents.

Featured Stories

Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.

Read the rest here:

Short Interest in Ipsen S.A. (OTCMKTS:IPSEY) Declines By 78.6% - Defense World

What is growth hormone deficiency?

Growth hormone deficiency (GHD), also known as dwarfism or pituitary dwarfism,is a condition caused by insufficient amounts of growth hormone in the body. Children with GHD have abnormally short stature with normal body proportions. GHD can be present at birth (congenital) or develop later (acquired). The condition occurs if the pituitary gland makes too little growth hormone. It can be also the result of genetic defects, severe brain injury or being born without a pituitary gland. In some cases, there is no clear cause identified. Sometimes, GHD can be associated with lower levels of other hormones, such as vasopressin (which controls water production in the body), gonadotropins (which controls the production of male and female sex hormones), thyrotropins (which control the production of thyroid hormones) or adrenocorticotrophic hormone (which controls the adrenal gland and related hormones).

Slow growth or absence of growth

Short stature (below the fifth percentile compared to other children of the same age and sex)

Absent or delayed sexual development during puberty

Headaches

Symptoms of other pituitary hormone deficiencies that may co-exist with growth hormone deficiency:

Absent or delayed sexual development during puberty

Increased urination and amount of urine

Excessive thirst

Facial abnormalities can be present in a small group of children with GHD, typically caused by pituitary defects.

A physical exam and measurement of height, weight, arms and leg lengths are the first steps to diagnosis, in addition to thorough medical history. Blood tests to measure the levels of growth hormone in the body as well as the levels of other hormones. Imaging tests including X-rays and MRI of the head may be helpful in narrowing down the underlying disorder causing GHD by revealing abnormalities of the hypothalamus or the pituitary glands.

Some cases of GHD can be treated with the use of synthetic growth hormone under the supervision of a pediatric endocrinologist. If other hormone deficiencies exist, other hormones can be given in addition to synthetic growth hormone.

See the article here:

Growth Hormone Deficiency | Johns Hopkins Medicine

Having a good height is nothing less than a blessing. Being tall is one of the elements of a perfect physical appearance which also creates a lasting impression on others. Call yourself lucky if you are blessed with it. Anywhere between 5 feet 6 inches and above is often considered a good height for females. For males, it is somewhere between 5 feet 8 inches and above.

You will be baffled to know that there is a person who stands around 8 feet tall. Yes, you heard that right. He is the tallest person in the world.

The Guinness World Records named Sultan Kosen the tallest person in the world. He is the first-ever man who stands over 8 feet tall out of the ten confirmed and reliable cases in the history of human existence. Sultan is a part-time farmer from Turkey. When he took the iconic title of the Tallest living man, he measured 8 feet 1 inch.

Two years later, Sultan turned 26 years old. He was measured again in Ankara. By that time, his height went up to 8 feet 2.8 inches.

Sultan was born on 10th December 1982. Interestingly, he did not start his incredible growth spurt until he turned 10 years old. The rest of his family, including his parents and four siblings, have an average height. Due to his gigantic size, Sultan could never finish his school. He, however, started working as a farmer to support his family.

Sultans unique growth and massive height are caused by the condition known as pituitary gigantism. It is the result of the overproduction of growth hormones.

Human growth hormone is released from the pituitary gland in the brain. If the gland is damaged by a tumor, it may release too much or too little hormone. When released too much, the condition may lead to overproduction of large hands, painful joints, and thickening of the bones.

In an interview, Sultan funnily described that being tall has its advantages. He can help his mother out with daily jobs and chores such as hanging curtains, changing a broken bulb, and others. However, the condition comes with many disadvantages too. It becomes challenging to find the right size of shoes and clothes or even to drive a car, for that matter.

Apart from being the tallest man in the whole wide world, Sultan Koser has other records in his name. He holds the title of living person with the largest hands. Each of his hands measures 28.5 centimeters from the wrist to the tip of the middle finger.

Previously, he held the title for the largest foot on a living person. His left foot measured 36.5 centimeters, and his right one measured 35.5 centimeters.

On a personal front, Sultan is married to Merve Dibo. His wife is nine years younger than him and stands 5 feet 9 inches tall. They met through a mutual friend.

Ever since he has become the record-holder of the Guinness World Records, Sultan has accomplished many of his dreams. He received life-saving medical treatment to stop himself from growing further. He also swapped his farming for Hollywood and bagged a role in the movie, Achieving the Impossible in 2016.

Keep in touch for more.

Here is the original post:

Who is the Tallest Living Man in the World? Meet Sultan Ksen - TheTealMango

When faced with conditions that are too dry, salty, or cold, most plants try to conserve resources. They send out fewer leaves and roots and close up their pores to hold in water. If circumstances dont improve, they eventually die.

Schrenkiella parvula is a plant that can grow even thrive in extremely salty conditions. Researchers in the Dinneny Lab study this plant to understand this special adaptation, and how they might be able to modify other plants to withstand similarly stressful environments. (Image credit: Jos Dinneny)

But some plants, known as extremophytes, have evolved to handle harsh environments. Schrenkiella parvula, a scraggly, branching member of the mustard family, doesnt just survive in conditions that would kill most plants it thrives in them. It grows along the shores of Lake Tuz in Turkey, where salt concentrations in the water can be six times higher than in the ocean. In a recent paper published in Nature Plants, researchers at Stanford University found that Schrenkiella parvula actually grows faster under these stressful conditions.

Most plants produce a stress hormone that acts like a stop signal for growth, said Jos Dinneny, an associate professor of biology at Stanford, who is senior author of the paper. But in this extremophyte, its a green light. The plant accelerates its growth in response to this stress hormone.

Dinneny and his colleagues are studying Schrenkiella parvula to better understand how some plants cope with challenging conditions. Their findings could help scientists engineer crops that are able to grow in lower-quality soil and adapt to the stresses of climate change.

With climate change, we cant expect the environment to stay the same, said Ying Sun, a postdoctoral researcher at the Salk Institute who earned her doctorate at Stanford and is a lead author on the paper. Our crops are going to have to adapt to these rapidly changing conditions. If we can understand the mechanisms that plants use to tolerate stress, we can help them do it better and faster.

Schrenkiella parvula is a member of the Brassicaceae family, which contains cabbage, broccoli, turnips, and other important food crops. In areas where climate change is expected to increase the duration and intensity of droughts, it would be valuable if these crops were able to weather or even thrive in those dry spells.

When plants encounter dry, salty, or cold conditions all of which create water-related stress they produce a hormone called abscisic acid, or ABA. This hormone activates specific genes, essentially telling the plant how to respond. The researchers examined how several plants in the Brassicaceae family, including Schrenkiella parvula, responded to ABA. While the other plants growth slowed or stopped, the roots of Schrenkiella parvula grew significantly faster.

Schrenkiella parvula is closely related to the other plants in the study and has a very similar-sized genome, but ABA is activating different sections of its genetic code to create a completely different behavior.

That rewiring of that network explains, at least partially, why were getting these different growth responses in stress-tolerant species, Dinneny said.

Image of an S. parvula root taken with a confocal microscope. (Image credit: Prashanth Ramachandran)

An overview of Ying Suns research by Neil E. Robbins II, PhD 17, a former graduate student in the Dinneny Lab. This comic was originally released April 14, 2017, on Neiler Comics. (Image credit: Neil E. Robbins II)

Understanding this stress response and how to engineer it in other species could help more than just food crops, Dinneny said. Schrenkiella parvula is also related to several oilseed species that have the potential to be engineered and used as sustainable sources of jet fuel or other biofuels. If these plants can be adapted to grow in harsher environmental conditions, there would be more land available for cultivating them.

You want to be growing bioenergy crops on land that is not suitable for growing food say, an agricultural field that has degraded soil or has accumulated salinity because of improper irrigation, Dinneny said. These areas are not prime agricultural real estate, but land that would be abandoned otherwise.

Dinneny and his colleagues are continuing to investigate the network of responses that could help plants survive in extreme conditions. Now that they have an idea of how Schrenkiella parvula sustains its growth in the face of limited water and high salinity, they will try to engineer related plants to be able to do the same by tweaking which genes are activated by ABA.

Were trying to understand what the secret sauce is for these plant species what allows them to grow in these unique environments, and how we can use this knowledge to engineer specific traits in our crops, Dinneny said.

Additional Stanford co-authors of this research include research associate Lina Duan, postdoctoral scholar Prashanth Ramachandran, and graduate student Andrea Ramirez. Other coauthors are from Louisiana State University and the Salk Institute for Biological Studies. Dinneny is a member of Stanford Bio-X.

This work was funded by the U.S. Department of Energy, the Carnegie Institution for Science, the National Science Foundation, the Rural Development Association of South Korea, and the HHMI-Simons Faculty Scholars program.

To read all stories about Stanford science, subscribe to the biweeklyStanford Science Digest.

Continue reading here:

'Extreme' plants grow faster in the face of stress | Stanford News - Stanford University News